1-5 of 5 results for subject:Donanemab
Librarians' tools
- Search time
- 0.176 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Donanemab
- We searched for
- subject_t:Donanemab OR subject_t:N3pG OR subject_ses:525358
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
Publisher
To ask His Majesty's Government what assessment they have made of clinical trials of donanemab and lecanemab for treating Alzheimer's conditions; and whether they plan to provide those drugs through the NHS.
To ask His Majesty's Government what assessment they have made of clinical trials of donanemab and lecanemab for treating Alzheimer's conditions; and whether they plan to provide those drugs through the NHS.
In England, the National Institute for Health and Care Excellence (NICE) is responsible for assessing whether new medicines should be routinely funded by the National Health Service, based on a careful evaluation of clinical and cost effectiveness.
NICE is currently evaluating both lecanemab and donanemab and has not yet published final guidance. NICE was unable to recommend either treatment in its final draft guidance, concluding that the benefits observed in clinical trials, when weighed against the risks and the overall cost, meant they could not currently be considered good value for the NHS. NICE’s independent Appeal Panel has upheld appeals against NICE’s draft recommendations, and its Appraisal Committee will meet to consider the appraisals on 10 June.
The Government has not made a separate assessment of the clinical trials beyond NICE’s independent evaluation.
To ask the Secretary of State for Health and Social Care, when he expects NICE to publish the outcomes of the appeals on its final draft guidance on donanemab and lecanemab.
To ask the Secretary of State for Health and Social Care, when he expects NICE to publish the outcomes of the appeals on its final draft guidance on donanemab and lecanemab.
The appeals against the National Institute for Health and Care Excellence (NICE) recommendations on donanemab and lecanemab for the treatment of Alzheimer’s disease were heard by NICE’s independent appeal panel in January. The next steps of the appraisal will be subject to the outcome of the appeals, and NICE will update its stakeholders in due course.
This briefing focuses on two disease-modifying dementia drugs that are currently being appraised by the National Institute for Health and Care Excellence (NICE): lecanemab and donanemab
This briefing focuses on two disease-modifying dementia drugs that are currently being appraised by the National Institute for Health and Care Excellence (NICE): lecanemab and donanemab
To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on its decision not to recommend the use of donanemab and lecanemab for Alzheimer's patients by the NHS.
To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on its decision not to recommend the use of donanemab and lecanemab for Alzheimer's patients by the NHS.
Department officials regularly discuss a range of issues with colleagues in the National Institute for Health and Care Excellence (NICE), including the progress of specific appraisals. NICE develops its guidance independently in line with its established methods and processes, and the Department is not able to direct NICE as to the substance of its recommendations. These are very difficult decisions to make, and it is right that they are taken by an independent committee on the basis of the available evidence.
NICE has not yet published final guidance on either lecanemab or donanemab. NICE published final draft guidance on 19 June 2025, and stakeholders now have an opportunity to lodge an appeal. NICE currently expects to publish final guidance in July this year.
To ask the Secretary of State for Health and Social Care, whether he has had discussions with the Department of Health in Northern Ireland on the use of (a) Lecanemab and (b) Donanemab in the treatment of dementia.
To ask the Secretary of State for Health and Social Care, whether he has had discussions with the Department of Health in Northern Ireland on the use of (a) Lecanemab and (b) Donanemab in the treatment of dementia.
The Department is working closely together with system partners to plan for the implementation of new dementia medicines such as lecanemab and donanemab, should they be granted a marketing authorisation in the United Kingdom and a positive National Institute for Health and Care Excellence (NICE) recommendation. Partners include the Medicines and Healthcare products Regulatory Agency, NICE, NHS England, the Office for Life Sciences, and the devolved administrations, including the Department of Health in Northern Ireland.